Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


An HIV Vaccine: An Unfulfilled Promise—Episode 4, Looking Toward a Fulfilled Promise

Listen to Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina Russell conclude this series by reiterating where we are now after 40 years of research and discussing what might it look like when an HIV vaccine is developed.
person default
Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD , PGD (Research Ethics). MBE (Research Ethics), CIP
person default
Peter Godfrey-Faussett, MBBS, FRCP(UK)
person default
Nina D. Russell, MD
Released: July 16, 2021

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina Russell discuss promising advances in the field of HIV vaccine research and how we can prepare for optimal rollout of an eventual HIV vaccine.


Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD , PGD (Research Ethics), MBE (Research Ethics), CIP
Senior Principal Clinical Research Scientist
Center for Microbiology Research
Research Professor
Departments of Global Health and Obstetrics and Gynecology
University of Washington,
Nairobi, Kenya
Seattle, Washington

Peter Godfrey-Faussett, MBBS, FRCP(UK)
Science Advisor
United Nations Joint Programme on HIV (UNAIDS)
Professor of Infectious Diseases and International Health
London School of Hygiene and Tropical Medicine
London, United Kingdom

Nina Russell, MD
Director for TB and HIV Prevention
Bill & Melinda Gates Foundation
Seattle, Washington

Link to the HIV unmuted series from IAS:


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with:
Educational grants provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) presents expert faculty discussing the barriers and solutions to expanding PrEP uptake, from a nursing perspective

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Christopher Fox, MSN, RN, ANP-BC, AAHIVS
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2022 Expired: June 13, 2023

Dr Michelle Collins-Ogle and Clinical Care Options (CCO): HIV postexposure prophylaxis is recommended following a potential sexual exposure.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 26, 2022

Clinical Care Options (CCO): expert commentary on major findings from EPIC-NSW and next steps in PrEP strategies and populationwide HIV prevention efforts

Prof. Don Smith Released: March 18, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): There are key management considerations for patients initiating LA cabotegravir for PrEP

person default Jason Schafer, PharmD, MPH Released: March 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings